Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop

ZJ Gu, V Costes, ZY Lu, XG Zhang, V Pitard, JF Moreau, R Bataille, J Wijdenes, JF Rossi, B Klein

Blood (1996) 88 (10): 3972–3986.

https://doi.org/10.1182/blood.V88.10.3972.bloodjournal88103972

Published: 1996

Journal Articles

Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells

E Sporeno, R Savino, L Ciapponi, G Paonessa, A Cabibbo, A Lahm, K Pulkki, RX Sun, C Toniatti, B Klein

Blood (1996) 87 (11): 4510–4519.

https://doi.org/10.1182/blood.V87.11.4510.bloodjournal87114510

Published: 1996

Journal Articles

Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments

ZY Lu, H Brailly, J Wijdenes, R Bataille, JF Rossi, B Klein

Blood (1995) 86 (8): 3123–3131.

https://doi.org/10.1182/blood.V86.8.3123.3123

Published: 1995

Journal Articles

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

R Bataille, B Barlogie, ZY Lu, JF Rossi, T Lavabre-Bertrand, T Beck, J Wijdenes, J Brochier, B Klein

Blood (1995) 86 (2): 685–691.

https://doi.org/10.1182/blood.V86.2.685.bloodjournal862685

Published: 1995

Journal Articles

Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells

ZY Lu, XG Zhang, C Rodriguez, J Wijdenes, ZJ Gu, B Morel-Fournier, JL Harousseau, R Bataille, JF Rossi, B Klein

Blood (1995) 85 (9): 2521–2527.

https://doi.org/10.1182/blood.V85.9.2521.bloodjournal8592521

Published: 1995

Journal Articles

Interleukin-6 in human multiple myeloma

B Klein, XG Zhang, ZY Lu, R Bataille

Blood (1995) 85 (4): 863–872.

https://doi.org/10.1182/blood.V85.4.863.bloodjournal854863

Published: 1995

Journal Articles

Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies

FA Montero-Julian, B Klein, E Gautherot, H Brailly

Blood (1995) 85 (4): 917–924.

https://doi.org/10.1182/blood.V85.4.917.bloodjournal854917

Published: 1995

Journal Articles

Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle- cell lymphomas and t(11q13)-associated leukemias

R Rimokh, F Berger, C Bastard, B Klein, M French, E Archimbaud, JP Rouault, B Santa Lucia, L Duret, M Vuillaume

Blood (1994) 83 (12): 3689–3696.

https://doi.org/10.1182/blood.V83.12.3689.3689

Published: 1994

Journal Articles

Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma

XG Zhang, JP Gaillard, N Robillard, ZY Lu, ZJ Gu, M Jourdan, JM Boiron, R Bataille, B Klein

Blood (1994) 83 (12): 3654–3663.

https://doi.org/10.1182/blood.V83.12.3654.3654

Published: 1994

Journal Articles

Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? [letter; comment]

M Boccadoro, G Gallone, R Frieri, A Pileri, R Bataille, B Klein

Blood (1993) 82 (11): 3507–3508.

https://doi.org/10.1182/blood.V82.11.3507.3507

Published: 1993

Journal Articles

gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro

M Portier, XG Zhang, E Caron, ZY Lu, R Bataille, B Klein

Blood (1993) 81 (11): 3076–3082.

https://doi.org/10.1182/blood.V81.11.3076.3076

Published: 1993

Journal Articles

Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance [letter; comment]

R Bataille, B Klein

Blood (1992) 80 (9): 2433–2434.

https://doi.org/10.1182/blood.V80.9.2433.2433

Published: 1992

Journal Articles

C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system

R Bataille, M Boccadoro, B Klein, B Durie, A Pileri

Blood (1992) 80 (3): 733–737.

https://doi.org/10.1182/blood.V80.3.733.733

Published: 1992

Journal Articles

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia

B Klein, J Wijdenes, XG Zhang, M Jourdan, JM Boiron, J Brochier, J Liautard, M Merlin, C Clement, B Morel-Fournier

Blood (1991) 78 (5): 1198–1204.

https://doi.org/10.1182/blood.V78.5.1198.1198

Published: 1991

Journal Articles

Serum beta-2-microglobulin (beta 2m) in myeloma: toward a simple prognostic stratification using beta 2M and acute-phase proteins? [letter; comment]

R Bataille, B Klein

Blood (1991) 77 (7): 1616–1617.

https://doi.org/10.1182/blood.V77.7.1616.1616

Published: 1991

Journal Articles

Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication

S Navarro, N Debili, JP Le Couedic, B Klein, J Breton-Gorius, J Doly, W Vainchenker

Blood (1991) 77 (3): 461–471.

https://doi.org/10.1182/blood.V77.3.461.461

Published: 1991

Journal Articles

Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells [see comments]

XG Zhang, R Bataille, M Jourdan, S Saeland, J Banchereau, P Mannoni, B Klein

Blood (1990) 76 (12): 2599–2605.

https://doi.org/10.1182/blood.V76.12.2599.2599

Published: 1990

Journal Articles

Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma

XG Zhang, B Klein, R Bataille

Blood (1989) 74 (1): 11–13.

https://doi.org/10.1182/blood.V74.1.11.11

Published: 1989

Journal Articles

Phenotypic analysis of human myeloma cell lines

C Duperray, B Klein, BG Durie, X Zhang, M Jourdan, P Poncelet, F Favier, C Vincent, J Brochier, G Lenoir

Blood (1989) 73 (2): 566–572.

https://doi.org/10.1182/blood.V73.2.566.566

Published: 1989

Journal Articles

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6

B Klein, XG Zhang, M Jourdan, J Content, F Houssiau, L Aarden, M Piechaczyk, R Bataille

Blood (1989) 73 (2): 517–526.

https://doi.org/10.1182/blood.V73.2.517.517

Published: 1989

NARROW

Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop

Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells

Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells

Interleukin-6 in human multiple myeloma

Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies

Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle- cell lymphomas and t(11q13)-associated leukemias

Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma

Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? [letter; comment]

gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro

Serum levels of beta 2 microglobulin and interleukin-6 to differentiate monoclonal gammopathy of undetermined significance [letter; comment]

C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia

Serum beta-2-microglobulin (beta 2m) in myeloma: toward a simple prognostic stratification using beta 2M and acute-phase proteins? [letter; comment]

Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication

Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells [see comments]

Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma

Phenotypic analysis of human myeloma cell lines

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only